Dr. Lydia H. Pecker is a pediatric hematologist and Director of the Young Adult Clinic at the Sickle Cell Center for Adults at Johns Hopkins. Dr. Pecker received her undergraduate degree in Africana studies from Brown University and earned her M.D. at the University of Pennsylvania School of Medicine. She completed residency training at Children’s Hospital at Montefiore and completed a fellowship at Children’s National Medical Center and the National Institutes of Health’s National Heart, Lung and Blood Institute before joining the Hopkins faculty in 2016. Dr. Pecker's NIH and foundation-funded research focuses on reproductive health in people with ovaries and sickle cell disease. Dr. Pecker is rated as an Elite provider by MediFind in the treatment of Anemia. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Tubal Ligation, and Bone Marrow Transplant.

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of Anemia. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Ambroise Wonkam is a Pediatrics specialist and a Medical Genetics provider in Baltimore, Maryland. Dr. Wonkam is rated as an Elite provider by MediFind in the treatment of Anemia. His top areas of expertise are Anemia, Fragile X Syndrome, Pyle Disease, and Micrognathia.

Michael Auerbach is a Hematologist in Rosedale, Maryland. Dr. Auerbach is rated as an Elite provider by MediFind in the treatment of Anemia. His top areas of expertise are Iron Deficiency Anemia, Anemia, Hypophosphatemia, and Childhood Iron Deficiency Anemia.

Courtney Fitzhugh is a Hematologist in Baltimore, Maryland. Dr. Fitzhugh is rated as an Elite provider by MediFind in the treatment of Anemia. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Dr. Ahmet Baschat is director of the Center for Fetal Therapy and professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. His areas of clinical expertise include prenatal diagnosis and therapy of a wide range of fetal conditions including congenital diaphragmatic hernia, intrauterine growth restriction, twin-to-twin transfusion syndrome (TTTS), as well as other complications of monochorionic twin pregnancies. Dr. Baschat received his undergraduate and medical degrees from The Royal College of Surgeons in Ireland. He earned his doctorate in medicine (Dr. Med) from the University of Lübeck, where he also completed a residency in obstetrics and gynecology. Dr. Baschat also completed residencies at Newton-Wellesley Hospital and at University of Maryland Medical Center. He performed a fellowship in maternal-fetal medicine at University of Maryland Medical Center and went on to develop its Center for Advanced Fetal Care. Dr. Baschat joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Baschat was professor and director of Maternal-Fetal Medicine and the Section of Fetal Therapy at the University of Maryland School of Medicine. Dr. Baschat’s research interests include interventions and management techniques for fetal growth restriction and placental insufficiency. He has also done extensive research on the use of high resolution prenatal ultrasound techniques, including Doppler and fetal echocardiography, to predict and detect fetal complications. Dr. Baschat serves on a variety of boards and is a member of the American Congress of Obstetricians and Gynecologists (ACOG), the International Society of Ultrasound in Obstetrics & Gynecology and the International Fetal Medicine and Surgery Society. He has been recognized with several awards and honors, including the 2010 Award for Excellence in Research by the Society for Maternal-Fetal Medicine. Dr. Baschat’s passion for developing an individualized care plan for each of his patients has been the hallmark of his practice. Dr. Baschat is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Twin-To-Twin Transfusion Syndrome, Intrauterine Growth Restriction, Bilateral Renal Agenesis Dominant Type, Diaphragmatic Hernia, and Endoscopy.

"Dr. James Casella is a professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. As the Johns Hopkins’ Rainey Professor of Pediatric Hematology, Dr. Casella is chief of the Division of Pediatric Hematology at Johns Hopkins Children's and director of the Basic and Translational Research Program in Sickle Cell Disease, Comprehensive Sickle Cell Center and the Maryland Hemophilia Treatment Center at Johns Hopkins. He supervises several labs investigating the cellular and molecular basis of pediatric blood-borne diseases. He is seeking to develop better treatments for sickle cell disease and the prevention of central nervous system complications of this disorder, including stroke. Dr. Casella received his undergraduate degree in mathematics from Union College. He earned his M.D. from SUNY of Syracuse and completed a residency in pediatrics at Johns Hopkins University School of Medicine, where he was subsequently a fellow in hematology/oncology. He has been a member of the Johns Hopkins’ faculty since 1983. A research scientist as well as a clinician, he co-directs the hematology/oncology fellowship program at Johns Hopkins Hospital and is an adjunct senior investigator (Pediatric Oncology Branch) in the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health. He is also director of the NHLBI-funded K12 in benign hematology program at Johns Hopkins that trains young clinician/investigators in benign hematology and transfusion medicine. Dr. Casella has served on numerous university, hospital, and advisory committees, many geared toward hematology, pediatrics and transfusion. He has received many awards from the Johns Hopkins Hospital, including the Alexander ""Buck"" Schaffer Award for Outstanding Contribution to the Teaching of House Officers. He and a colleague created the Johns Hopkins/St. Agnes Comprehensive Hemophilia Clinic to improve care for patients with the disease.". Dr. Casella is rated as an Elite provider by MediFind in the treatment of Anemia. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Dr. Moonjung Jung is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Dr. Jung graduated Summa Cum Laude from Ewha Womans University College of Medicine in Seoul, South Korea. She then completed the Internal Medicine residency training at Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX and the Hematology and Medical Oncology fellowship training at National Institutes of Health, Bethesda, MD. In 2016, Dr. Jung joined the Rockefeller University as an Instructor in Clinical investigation. She received M.S. in Clinical Investigation from the Rockefeller University. In 2021, Dr. Jung joined the Johns Hopkins University School of Medicine as faculty in the Division of Hematology. Dr. Jung is rated as an Advanced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, and Anemia.

Dr. Lance received her undergraduate degree from Princeton University and received her medical degree from the Medical University of South Carolina. She did residency in general pediatrics at Childrens Hospital Los Angeles and additional specialized residency training in neurodevelopmental disabilities at the Kennedy Krieger Institute. She received additional research training at Kennedy Krieger Institute/Johns Hopkins University School of Medicine and has a Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. Selected Publications Gipson TT*, Lance EI*, (*co-first authors), Albury RA, Gentner MB, Leppert ML. Disparities in Identification of Comorbid Diagnoses in Children with ADHD. Clin Pediatr 2015 54(4):376-81. Lance EI*, Sreenivasan AK*, (*co-first authors), Zabel TA, Kossof EH, Comi AM. Aspirin Use in Sturge-Weber Syndrome: Side Effects and Clinical Outcomes. J Child Neurol 2013 28(2): 213-218. Lance EI, Casella JF, Everett AD, Barron-Casella E. Proteomic and Biomarker Studies and Neurological Complications of Pediatric Sickle Cell Disease. Proteomics Clin Appl 2014 8(11-12):813-27. Lance EI, Comi AM, Johnston MV, Casella JF, Shapiro, BK. Risk Factors for Attention and Behavioral Issues in Pediatric Sickle Cell Disease. Clin Pediatr ahead of print 2015 Jul 6. Lance EI, Dupont BR, Holden KR. Expansion of the Deletion 13q Syndrome Phenotype: A Case Report. J Child Neurol 2007 22(9): 1124-1127. Lance EI, Lanier K, Zabel TA, Comi AM. Stimulant Use in Patients with Sturge-Weber Syndrome: Safety and Efficacy. Ped Neurol 2014 51(5): 675-680. Lance EI, Shapiro BK. Confounding Diagnoses in the Neurodevelopmental Disabilities Population: A child with Hearing Loss, Absence Epilepsy, and Attention Deficit Hyperactivity Disorder. J Child Neurol 2013 28(5): 645 – 647. Lance EI, York, JM, Lee LC, Zimmerman, AW. Association between Regression and Self Injury among Children with Autism. Res Dev Disabil 2014 35(2): 408 – 413. Dr. Lance is rated as an Advanced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Anemia, Autism Spectrum Disorder, 15q11.2 Microdeletion, and Jacobsen Syndrome.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is rated as a Distinguished provider by MediFind in the treatment of Anemia. Her top areas of expertise are Sickle Cell Disease, Hemolytic Anemia, Hemoglobinopathy, and Congenital Hemolytic Anemia.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as a Distinguished provider by MediFind in the treatment of Anemia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Onyebuchi Ogbuagu is a primary care provider, practicing in Family Medicine and General Practice in Baltimore, Maryland. Dr. Ogbuagu is rated as an Advanced provider by MediFind in the treatment of Anemia. His top areas of expertise are Peptic Ulcer, Necrosis, Cellulitis, and Erosive Pustular Dermatosis of the Scalp.

Dr. Fatima Sheikh is Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include general internal medicine and geriatric medicine. Dr. Sheikh is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Blood Clots, Anemia, and Dementia.

Michelle Kush, M.D., is an obstetrics and gynecology physician specializing in maternal fetal medicine. She has expertise in all aspects of the field, including fetal growth restriction, fetal anomalies and complex maternal conditions during pregnancy. Dr. Kush obtained her medical degree from Loyola University Chicago’s Stritch School of Medicine in Maywood, Illinois. She completed a residency in obstetrics and gynecology and a fellowship in maternal fetal medicine at the University of Maryland Medical Center (UMMC) in Baltimore. Dr. Kush remained with the Department of Obstetrics, Gynecology and Reproductive Sciences at UMMC for another 10 years, serving as the medical director of perinatal outreach, department director of maternal transports and a member of the hospital ethics committee. More recently, Dr. Kush has been a member of a local, private maternal fetal medicine group. She also continues to participate in the University of Maryland’s master’s in genetic counseling program as an instructor and a member of its executive committee. Dr. Kush is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Twin-To-Twin Transfusion Syndrome, Anemia, Newborn Polycythemia, Intrauterine Growth Restriction, and Endoscopy.

Dr. Michael Cole is a distinguished graduate of the US Air Force Academy (2006), and as an Alberta Bart Holaday Scholar went on to complete his Doctor of Philosophy in Biochemistry (2010) at University of Oxford under the direction of Prof Paul Wentworth Jr. and Prof Bob Sim. He focused his research on peptide chemistry and acyl group reactivity in thioester-containing proteins such as complement proteins, C3 and C4. He fulfilled his Air Force commitment as a chemist and Assistant Professor of Chemistry at the US Air Force Academy. He came to Johns Hopkins University for medical school in 2014. Since that time, he has stayed at Johns Hopkins completing his medical degree (2018), internal medicine residency training (2021), and hematology fellowship (2024). In 2024, he joined the Division of Hematology as an Instructor. Dr. Cole is rated as an Experienced provider by MediFind in the treatment of Anemia. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, and Atypical Hemolytic Uremic Syndrome (aHUS).

Dr. Li Hua is a hospitalist at Johns Hopkins Howard County Medical Center. Dr. Hua only sees patients who are in the hospital, she does not have outpatient clinic appointments. Dr. Hua is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Sickle Cell Disease, Sepsis, Ogilvie Syndrome, Hip Replacement, and Gastrostomy.

Dr. Joann Bodurtha is a professor of genetic medicine, pediatrics, and oncology at the Johns Hopkins University School of Medicine. Dr. Bodurtha is co-director of the regional genetics network NYMAC, co-director of the Biological Mechanisms theme in the Genes to Society Curriculum, co-director of the BIRCWH Advisory Board, Physician Advisor for the Dept. of Genetic Medicine, a member of the Advisory Committee of the JH-NHGRI Genetic Counseling program, and a member of the Johns Hopkins Medicine Institutional Review Board. She has appointments in the School of Public Health and School of Nursing. Her research focuses on risk communication and interdisciplinary genetic education. Prior to joining Johns Hopkins, Dr. Bodurtha was a professor of human and molecular genetics at VCU, where she had faculty appointments in the Departments of Pediatrics, Obstetrics-Gynecology, and Preventive Medicine and Community Health. She received her B.A. from Swarthmore College and her M.D. and M.P.H. with honors from Yale. After a year of research at the Nagasaki University School of Medicine as a Luce Scholar, she completed her residency in pediatrics at Children’s Hospital of Philadelphia and worked as a USPHS physician on the Turtle Mountain Chippewa Reservation in North Dakota. She completed her medical genetics fellowship at Virginia Commonwealth University (VCU) in 1987. Dr. Bodurtha joined the Johns Hopkins faculty in 2011. At VCU, Dr. Bodurtha helped start the Masters in Genetic Counseling program in 1990 and the Va-LEND (Leadership Education in Neurodevelopmental Disabilities) program in 1995. She served on the American Academy of Pediatrics Committee on Native American Child Health for ten years. She was the Richmond YMCA Woman of the Year in Science and Medicine in 1997. She received the VCU School of Medicine first Innovation in Teaching Award in 1999, the SCHEV Outstanding Faculty Award in 2006, the Genetic Alliance Art of Listening Award in 2008, the AUCD Professional Achievement Award in 2009, and the VCU WISDM Professional Achievement Award in 2010. A member of the Leadership Metro Richmond Class of 2000, she served as president of the WISDM (Women in Science, Dentistry, and Medicine) organization at VCU from 2000 to 2003. She has written more than 150 scientific articles, book chapters, and reviews and supervised more than 100 graduate students. She is committed to improving access to genetic services and helping make all communities be more welcoming. Dr. Bodurtha is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Ehlers-Danlos Syndrome (EDS), Micrognathia, Inborn Renal Aminoaciduria, and Blepharophimosis.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Squamous Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC).

Dr. Agee is medical director for the Bayview Medical Offices. Her practice includes all aspects of primary care medicine, including prevention, pap smears and cortisone shots. Dr. Agee is from Annapolis. She attended Wake Forest University School of Medicine, in North Carolina, trained in general internal medicine at Johns Hopkins Bayview Medical Center. Dr. Agee is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Glucocorticoid-Remediable Aldosteronism, Hypertension, Familial Hypertension, and Type 2 Diabetes (T2D).

"In her first decade as a pediatric oncologist, Dr. Symons already has shown an impressive ability to juggle multiple research projects, in addition to caring for patients. One of Dr. Symons' research pursuits focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. The basis of her work stems from the theory that cancer patients' immune systems should recognize tumor cells as foreign and destroy them. This doesn't happen, theorizes Dr. Symons, because the immune system attacks only those cells it perceives as dangerous—not cancer cells, which it sees simply as foreign. That's where her research comes into play. Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will ""awaken"" patients' immune systems to the danger of existing cancer cells and, in turn, elicit an immune response. In a separate yet equally compelling research endeavor, Dr. Symons is working to increase the availability of donors for children whose cancer requires bone marrow transplants (BMTs) as a potentially lifesaving treatment. ""It can be challenging to find a 'matched' donor,"" says Dr. Symons, who explains that only about 40 percent of patients who require a BMT find a matched donor. ""Sometimes, we don't have the benefit of time, because remissions can be short-lived. But almost all patients have a half-matched donor: a parent, sibling, or child,"" adds Dr. Symons, who is examining ways to reduce BMT-related complications ordinarily associated with half-matched donors after ablative (high dose) chemotherapy. ""Like anything else that's new, it will take some time to prove that this is a feasible option that's safe,"" she says. But she's optimistic. ""It has the potential to revolutionize BMT."" Dr. Symons knows it's worth the wait. ""Seeing the research I do in the lab translate into clinical trials, then seeing patients in these trials survive long term, is incredibly rewarding,"" she says.". Dr. Symons is rated as an Experienced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Graft Versus Host Disease (GvHD), Aplastic Anemia, Anemia, Leukemia, and Bone Marrow Transplant.